Nemolizumab Sustains Atopic Dermatitis Control Through 3 Years
Long-term data show nemolizumab maintained skin clearance and itch control in atopic dermatitis patients through 3 years of continuous therapy, reinforcing its durability profile.
Topic
Il 31
Topic
Il 31
Nemluvio Shows Three-Year Durability in Atopic Dermatitis
Galderma presented three-year Nemluvio® data at Fall Clinical 2026 showing deep, lasting lesion and itch responses in atopic derm…
Nemolizumab Sustains Atopic Dermatitis Response at 3 Years
Three-year extension data show nemolizumab sustains response in adults with moderate-to-severe atopic dermatitis, according to co…
Galderma Presents New Nemluvio Data in Atopic Dermatitis Aged 12+
Galderma has presented new Nemluvio (nemolizumab) data showing responses in patients with atopic dermatitis aged 12 and older, ad…